Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer

doi:10.4251/wjgo.v2.i1.19

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 1

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4041)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-5) series, Tables (1-2) series.

Item

Count

PDF

410

HTML

3269

Figures (1-5)

184

Tables (1-2)

178

Sum=4041

Jan 15, 2010 (publication date) through Apr 23, 2024

Times Cited of This Article

Times Cited (43)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastrointest Oncol. Jan 15, 2010; 2(1): 19-30
Published online Jan 15, 2010. doi: 10.4251/wjgo.v2.i1.19

Full Size Figure Download Figure

Figure 2 Pharmacodynamics during HIPEC after intravenous administration of 400 mg/m² of 5-fluorouracil given simultaneously with intraperitoneal chemotherapy in 3 L of chemotherapy solution. (Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacology of perioperative 5-fluorouracil. Submitted for publication).

Citation: Sugarbaker PH, Van der Speeten K, Stuart OA. Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol 2010; 2(1): 19-30
URL: https://www.wjgnet.com/1948-5204/full/v2/i1/19.htm
DOI: https://dx.doi.org/10.4251/wjgo.v2.i1.19